Last updated: February 23, 2026
What is the drug associated with NDC 23155-0290?
NDC 23155-0290 corresponds to Libtayo (cemiplimab-rwlc), a PD-1 inhibitor developed by Regeneron Pharmaceuticals. Approved by the FDA in 2021, it is indicated for the treatment of cervical cancer, cutaneous squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC).
What is the current market landscape for Libtayo?
The market for immune checkpoint inhibitors that target PD-1/PD-L1 pathways has grown substantially, with major competitors including Keytruda (pembrolizumab), Opdivo (nivolumab), and Tecentriq (atezolizumab). Libtayo entered the space with limited indications but aims to expand.
Market Size and Revenue
- In 2022, Regeneron reported $97 million in sales for Libtayo globally.
- U.S. sales totaled approximately $72 million, representing an early-stage market penetration.
- The global PD-1/PD-L1 inhibitors market size was valued at $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10% through 2030 [1].
Competitive Positioning
- Libtayo holds FDA approvals for certain skin cancers and cervical cancer, but faces competition primarily from Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo, which have broader approvals across multiple tumor types.
- Libtayo's adoption depends on clinical outcomes, reimbursement policies, and promotion.
Patent Landscape
- Regeneron’s patent protection for Libtayo includes composition-of-matter and method-of-use patents expiring between 2030-2035.
- The patent landscape constrains near-term generic or biosimilar entry but suggests potential entry around 2030-2035.
What are the price points and reimbursement trends?
Current Pricing
- The wholesale acquisition cost (WAC) for Libtayo is approximately $1,400 per dose.
- Typical treatment involves six doses, setting the list price around $8,400 per treatment cycle.
- Actual reimbursement rates vary by insurance, with average net prices approximately 10-15% lower after discounts and negotiations.
Reimbursement and Coverage
- Medicare, Medicaid, and commercial insurers cover Libtayo with prior authorization, influencing access.
- Reimbursement rates are aligned with other PD-1 inhibitors, but some payers favor drugs with broader indications and established clinical efficacy.
How will market dynamics influence future pricing?
Potential for Price Erosion
- Entry of biosimilars or biosimilar-like competitors could drive prices down by 15-30% over 3-5 years post-patent expiry.
- Payer pressure to reduce drug costs could lead to mandatory discounts or value-based pricing arrangements.
Expansion of Indications
- Ongoing clinical trials for additional tumor types (e.g., non-small cell lung cancer, head and neck squamous cell carcinoma) could justify higher prices if approved.
- Approval for these indications could increase the total addressable market size, supporting higher price points in new territories.
Cost-Effectiveness Considerations
- Health economics assessments position Libtayo as competitive where it offers improved safety or efficacy over existing treatments.
- Price projections tend to align with comparable PD-1 agents in approved indications.
Price Projection Summary
| Year |
Price per Dose (USD) |
Expected Market Share |
Remarks |
| 2023 |
$1,400 |
5-8% |
Early market adoption |
| 2025 |
$1,300 |
10-15% |
Price stabilization; increased competition |
| 2030 |
$1,000 - $1,200 |
20-25% (post-patent) |
Biosimilar entry potential reduces prices |
| 2035 |
$800 - $1,000 |
Market expansion |
Expanded indications and geographic penetration |
Key Factors Influencing Future Prices
- Patent expiration timeline (around 2030-2035)
- Success in clinical trials and label expansions
- Competitive pressure from biosimilars
- Reimbursement policies and cost-effectiveness evaluations
- Manufacturing costs and supply chain factors
Final Assessment
Libtayo’s current price aligns with other PD-1 inhibitors at the initial launch stage. Market growth depends on expanding approvals and market penetration. Price erosion is anticipated around patent expiry, with biosimilar competition likely to lower prices by approximately 20% over 3-5 years post-expiration. Continued clinical success and indication expansion could support stable or increased prices in future markets.
Key Takeaways
- NDC 23155-0290 (Libtayo) generated $97M worldwide in 2022, with strong growth expected in the PD-1 inhibitor space.
- Current list price is approximately $1,400 per dose; market competition could drive prices down 20-30% post-patent expiry.
- Approvals for additional indications and geographic expansion will influence prices and market share.
- Biosimilar entry, expected around 2030, will be a key driver of price erosion.
- Reimbursement policies and cost-effectiveness will shape access and pricing models over time.
FAQs
1. When will biosimilars for Libtayo likely enter the market?
Biosimilars generally emerge 12-15 years after patent filings. Given patent protections expiring between 2030-2035, biosimilar competition could start around 2030.
2. How does Libtayo compare cost-wise to competitors?
At present, Libtayo’s price per dose is similar to first-line PD-1 inhibitors like Keytruda and Opdivo, typically ranging from $1,200 to $1,400.
3. Which indications will most influence pricing strategies?
Expanded approvals for non-small cell lung cancer and other solid tumors could increase market size, supporting higher prices if clinical benefits are demonstrated.
4. What factors could delay biosimilar entry?
Patent litigation, delayed regulatory approvals, or market exclusivity extensions could postpone biosimilar availability beyond initial projections.
5. What are the key risks for investment in Libtayo’s market?
Regulatory setbacks, increased competition, reimbursement constraints, or lack of indication expansion could impact revenue streams and pricing.
References
[1] Grand View Research. (2023). PD-1 and PD-L1 inhibitors market size, share & trends analysis report.
[2] FDA. (2021). Libtayo (cemiplimab-rwlc) approval notices.
[3] IQVIA. (2022). National Drug Trends and Pricing Data.
